1114547-44-2

Upstream product

• 625-99-0 3-iodochlorobenzene 
• 1114547-42-0 (S)-2-{(3-chlorophenyl)amino}propan-1-ol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1114547-46-4 (S)-tert-butyl (3-chlorophenyl)(1-hydroxypropan-2-yl)carbamate 
• 1114547-50-0 (4S,5S)-1-(3-chlorophenyl)-3,3-difluoro-4-hydroxy-5-methylpyrrolidin-2-one 
• 1114545-63-9 2'-chloro-4'-{(2R,3S)-4,4-difluoro-3-hydroxy-2-methyl-5-oxopyrrolidin-1-yl}benzonitrile 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate

We previously reported that 4-(pyrrolidin-1-yl)benzonitrile derivative 1b was a selective androgen receptor modulator (SARM) that exhibited anabolic effects on organs such as muscles and the central nervous system (CNS), but neutral effects on the prostate. From further modification, we identified that 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2a showed strong AR binding affinity with improved metabolic stabilities. Based on these results, we tried to enhance the AR agonistic activities by modifying the substituents of the 5-oxopyrrolidine ring. As a consequence, we found that 4-[(2S,3S)-2-ethyl-3-hydroxy-5-oxopyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile (2f) had ideal SARM profiles in Hershberger assay and sexual behavior induction assay. Furthermore, 2f showed good pharmacokinetic profiles in rats, dogs, monkeys, excellent nuclear selectivity and acceptable toxicological profiles. We also determined its binding mode by obtaining the co-crystal structures with AR.

Cyclic amine compounds

The present invention relates to pharmaceutical agents which are agents for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; the pharmaceutical agents frailty suppressants, muscle strength enhance